ArticleCardiovascular diabetology2019

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.

Shih-Chieh Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.